58
1
17
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T7900 | BAY-474 | c-Met/HGFR | |
BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe | |||
T2293 | SGX-523 | Raf , p38 MAPK , c-Met/HGFR , Bcr-Abl | |
SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf. | |||
T5349 | SCR-1481B1 | c-Met inhibitor 2 | VEGFR , c-Met/HGFR |
SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor | |||
T6094 | MK-2461 | MK2461 | c-Met/HGFR |
MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with an average inhibitory concentration (IC50) of 2.5 nM. | |||
T6095 | JNJ-38877605 | c-Met/HGFR | |
JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. | |||
T10655 | c-Met inhibitor 1 | c-Met/HGFR | |
c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer. | |||
T6378 | AMG-458 | AMG 458 | c-Met/HGFR |
AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells. | |||
T37596 | Terevalefim | c-Met/HGFR | |
Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor. | |||
T6154 | SU11274 | Met Kinase Inhibitor,PKI-SU11274 | Apoptosis , VEGFR , FGFR , c-Met/HGFR , CDK , Autophagy |
SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2. | |||
T6260 | AMG-208 | AMG 208 | P450 , c-Met/HGFR |
AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1. | |||
T6117 | Tivantinib | ARQ 197 | Apoptosis , c-Met/HGFR |
Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. | |||
T3274 | S49076 | FGFR , c-Met/HGFR , TAM Receptor | |
S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs. | |||
T2680 | NVP-BVU972 | c-Met/HGFR | |
NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM. | |||
TQ0041 | Ningetinib Tosylate | VEGFR , c-Met/HGFR , TAM Receptor | |
Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively. | |||
T6128 | PHA-665752 | PHA 665752,PHA665752 | Apoptosis , VEGFR , FGFR , c-Met/HGFR , Bcr-Abl , Autophagy |
PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs. | |||
T11162 | EGFR-IN-8 | EGFR , c-Met/HGFR | |
EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC. | |||
T2419 | BMS-794833 | VEGFR , c-Met/HGFR | |
BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378. | |||
T15617 | JNJ-38877618 | OMO-1 | c-Met/HGFR |
JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively). | |||
T8409 | SYN1143 | RON-IN-1,AMG-1 | c-Met/HGFR |
SYN1143 (AMG-1) is a potent inhibitor of human RON and c-Met.In vitro kinase assays showed that compound I is a potent inhibitor of human RON and c-Met with IC50s of 9 and 4 nmol/L, respectively. | |||
T5478 | SRI 31215 TFA | SRI 31215 | c-Met/HGFR |
SRI 31215 TFA, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation with IC50s of 0.69 μM, 0.65 μM, 0.3 μM, | |||
T5467 | SAR125844 | SAR125884 | Apoptosis , c-Met/HGFR |
SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L) | |||
T9123 | DS-1205 | TAM Receptor | |
DS-1205 is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205 also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205 can inhibit cell migration in vitro an... | |||
T13194 | CSF1R-IN-2 | c-Fms , c-Met/HGFR , Src | |
CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively). | |||
T6907 | NPS-1034 | NPS1034,NPS 1034 | Apoptosis , c-Met/HGFR , TAM Receptor |
NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively. | |||
T4332 | c-Kit-IN-1 | PDGFR inhibitor 1,DCC-2618 | c-Met/HGFR , c-Kit |
c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM). | |||
T2496 | (Z)-Semaxinib | SU5416 | VEGFR |
(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition for FGFR, InsR, and EGFR. (Z)-Semaxinib is a quinolone derivative w... | |||
T2676 | PF-04217903 | c-Met/HGFR | |
MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity. | |||
T3209 | AMG-337 | AMG337 | c-Met/HGFR |
AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337(AMG337) inhibits MET kinase activity (IC50: < 5 nM). | |||
T5414 | Glumetinib | SCC244 | c-Met/HGFR |
Glumetinib (SCC244) (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM). | |||
TQ0219 | MK-8033 | c-Met/HGFR | |
MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met). | |||
T6517 | Golvatinib | E-7050 | VEGFR , c-Met/HGFR |
Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic ... | |||
T4426 | CEP-40783 | CEP 40783,RXDX-106 | c-Met/HGFR , TAM Receptor |
CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM). | |||
T10585 | Bozitinib | CBT-101,PLB-1001 | c-Met/HGFR |
Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily. | |||
T3455 | Merestinib | LY2801653 | Discoidin Domain Receptor (DDR) , FLT , c-Met/HGFR , ROS , ROS Kinase |
Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. Merestinib electively binds to c-Met, thereby inhibiting c-Met phosph... | |||
TQ0021 | Ningetinib | CT-053,CT053PTSA | VEGFR , c-Met/HGFR , TAM Receptor |
Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively. | |||
T9052 | XL092 | CL-092,JUN04542 | VEGFR , c-Met/HGFR , TAM Receptor |
XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders. | |||
T2699 | BMS 777607 | BMS777607,BMS-777607,BMS 817378 | c-Met/HGFR , TAM Receptor |
BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3 (IC50: 3.9/1.1/1.8/4.3 nM). BMS-777607 has been investigated for the basic science of Malignant Solid Tumour. | |||
T1661 | Crizotinib | PF-02341066 | c-Met/HGFR , ROS , ALK , Autophagy , ROS Kinase |
Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor. | |||
T6351 | MGCD-265 analog | MGCD-265,Glesatinib | Apoptosis , VEGFR , c-Met/HGFR |
MGCD-265 analog (Glesatinib) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 nM for c-Met and VEGFR2, respectively. | |||
T2054 | Altiratinib | DCC-2701 | VEGFR , Tie-2 , FLT , Trk receptor , c-Met/HGFR |
Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with an HGF antagonist... | |||
TQ0210 | Savolitinib | AZD-6094,Volitinib,HMPL-504 | c-Met/HGFR |
Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met). | |||
T8825 | Capmatinib 2HCl.H2O | INCB28060 2HCl.H2O,INC-280 2HCl.H2O,NVP-INC280 2HCl.H2O | c-Met/HGFR |
Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity. | |||
T2516 | Amuvatinib | MP470,HPK 56 | Apoptosis , FLT , c-Met/HGFR , c-RET , DNA/RNA Synthesis , PDGFR , c-Kit |
Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity. | |||
T3550 | X-376 | Ensartinib,X-396 | c-Met/HGFR , ALK |
X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic activity. Upon oral administration, X-396 binds to and inh... | |||
T1963 | Capmatinib | NVP-INC280,INC-280,INCB28060 | Apoptosis , c-Met/HGFR |
Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity. | |||
T17184 | Tyrosine kinase inhibitor | c-Met/HGFR , Tyrosine Kinases | |
Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents. | |||
T8416 | Capmatinib xHCl | INCB28060,Capmatinib hydrochloride(free base),INC280 | c-Met/HGFR |
Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activit... | |||
T4260 | Capmatinib 2HCl | INC-280 2HCl,INCB28060 2HCl | c-Met/HGFR |
Capmatinib 2HCl (INC-280 2HCl) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.Capmatinib 2HCl exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10, 000-... | |||
T22324 | Ensartinib hydrochloride | Ensartinib dihydrochloride,X-396 dihydrochloride | Others , Trk receptor , c-Met/HGFR , ALK |
Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of known crizotinib-resistant ALK mutations. It potently inhibits both... | |||
T3113 | Foretinib | GSK089,EXEL-2880,GSK1363089,XL880 | VEGFR , Tie-2 , c-Met/HGFR |
Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR. |
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T13108 | Pamufetinib | H2OL3Q4XRD,4-(2-Fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide,TAS-115 | VEGFR , c-Met/HGFR |
Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively). |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-01896 | HGFR/c-Met Protein, Mouse, Recombinant (His) | Mouse | HEK293 |
Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR... | |||
TMPY-01296 | HGFR/c-Met Protein, Human, Recombinant (His) | Human | HEK293 |
Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR... | |||
TMPY-01895 | HGFR/c-Met Protein, Mouse, Recombinant (hFc) | Mouse | HEK293 |
Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR... | |||
TMPY-05441 | HGFR/c-Met Protein, Human, Recombinant (hFc) | Human | HEK293 |
Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR... | |||
TMPY-00548 | HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant (His) | Cynomolgus,Rhesus | HEK293 |
Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR... | |||
TMPY-00718 | HGFR/c-Met Protein, Human, Recombinant (His & hFc) | Human | HEK293 |
Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR... | |||
TMPY-05607 | HGFR/c-Met Protein, Human, Recombinant (His & Avi), Biotinylated | Human | HEK293 |
Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR... | |||
TMPY-04379 | HGFR/c-Met Protein, Human, Recombinant (aa 956-1390, His & GST) | Human | Baculovirus-Insect Cells |
Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR... | |||
TMPY-03581 | HGFR/c-Met Protein, Rat, Recombinant (hFc) | Rat | HEK293 |
Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR... | |||
TMPY-00634 | HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant | Cynomolgus,Rhesus | HEK293 |
Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR... | |||
TMPY-06657 | HGFR/c-Met Protein, Rat, Recombinant (His) | Rat | HEK293 |
Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR... | |||
TMPY-02068 | HGFR/c-Met Protein, Canine, Recombinant (His) | Canine | HEK293 |
Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR... | |||
TMPK-00499 | HGFR/c-Met Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 |
c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene.The protein possesses tyrosine kinase activity. The primary single chain ... | |||
TMPK-00457 | HGFR/c-Met Protein, Human, Recombinant (His & Avi) | Human | HEK293 |
c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene.The protein possesses tyrosine kinase activity. The primary single chain ... | |||
TMPY-00546 | HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant (hFc) | Cynomolgus,Rhesus | HEK293 |
Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR... | |||
TMPY-06278 | HGFR/c-Met Protein, Cynomolgus, Rhesus, Recombinant (His), Biotinylated | Cynomolgus,Rhesus | HEK293 |
Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR... | |||
TMPJ-00415 | HGFR/c-Met Protein, Human, Recombinant (aa 25-932, His & Avi), Biotinylated | Human | Human Cells |
Hepatocyte growth factor receptor (HGF R) is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGF R is synthesized as a single chain precursor which un... |